Regeneron (REGN) Tops Q3 EPS by 40c; EYLEA Sales Rose 16%

November 4, 2016 6:31 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Regeneron (NASDAQ: REGN) reported Q3 EPS of $3.13, $0.40 better than the analyst estimate of $2.73. Revenue for the quarter came in at $1.22 billion versus the consensus estimate of $1.29 billion.

EYLEA sales rose 16% to $854 million, from $734 million in Q315.

2016 Financial Guidance(3)

The Company's updated full year 2016 financial guidance consists of the following components:

EYLEA U.S. net product sales

23% - 25% growth over 2015

(previously 20% - 25% growth over 2015)

Sanofi reimbursement of Regeneron commercialization-related expenses

$310 million - $335 million

(previously $310 million - $340 million)

Non-GAAP unreimbursed R&D(2) (4)

$945 million - $975 million

(previously $970 million - $1.01 billion)

Non-GAAP SG&A(2) (4)

$965 million - $995 million

(previously $980 million - $1.02 billion)

Effective tax rate

29% - 33%

(previously 33% - 41%)

Capital expenditures

$480 million - $510 million

(previously $480 million - $530 million)

For earnings history and earnings-related data on Regeneron (REGN) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings